This company has not started trading yet. The live 5-factor QL signal switches on automatically on its first session.
We are a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases. By leveraging our proprietary LYTAC (Lysosomal Targeting Chimera) platform, we have developed a pipeline of therapeutic candidates with the potential to provide deep and durable elimination of extracellular proteins that are inadequately addressed by currently available therapies.
From Lycia Therapeutics, Inc.'s Form S-1/A filed with the SEC on 2026-10-20. The issuer's own words — QuantLogix does not paraphrase it.
We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to advance the clinical development of our IgE portfolio consisting of LCA-0061 and LCA-0062, to advance clinical development of our Graves' disease program, LCA‑0321, and to advance our other research and development activities; as well as for working capital and for other general corporate purposes.
From Lycia Therapeutics, Inc.'s Form S-1/A filed with the SEC on 2026-10-20. Quoted from the prospectus.
The audited financial statements for this issuer are in its Form S-1/A filed 2026-10-20. QuantLogix only publishes figures it can read directly from the filing.
From Lycia Therapeutics, Inc.'s Form S-1/A filed with the SEC on 2026-10-20. Extraction is deterministic — the same filing always produces the same score; 637k characters of the document were scanned. Technology signals are lexical indicators, not a technical audit. Not investment advice; the debut itself will be this score's first grade.
Deal terms come from the public IPO calendar and change up to pricing — an expected date reads “to be announced” until the underwriters set it, and a range is not a final price. Implied market cap and float are arithmetic on those disclosed terms. Nothing on this page is a forecast or a recommendation.